新华制药公告称，其全资子公司新达制药收到国家药监局核准签发的沙格列汀二甲双胍缓释片（Ⅰ）、 （Ⅲ）《药品注册证书》。本品配合饮食和运动治疗，适用于2型糖尿病成人患者，为医保目录乙类品 种。2024年中国公立医疗机构该药品销售额约4.19亿元。获批有利于丰富公司降糖制剂系列、提升综合 竞争力，但药品销售受多种因素影响，存在不确定性。 ...

Core Viewpoint - COSCO Shipping has announced the suspension of new booking services for specific routes due to escalating conflicts in the Middle East, particularly affecting maritime traffic in the Strait of Hormuz [1] Group 1: Service Suspension Details - The company has decided to suspend all new booking services from global locations to the UAE (excluding Fujairah and Khor Fakkan), Qatar, Bahrain, Iraq, Saudi Arabia (excluding Jeddah), and Kuwait [1] - Additionally, all new booking services from the UAE (excluding Fujairah and Khor Fakkan), Qatar, Bahrain, Iraq, Saudi Arabia (excluding Jeddah), and Kuwait to global locations are also suspended [1] Group 2: Current Cargo Management - For cargo already on board, the company is conducting a comprehensive assessment of follow-up handling plans, including the exploration of potential alternative discharge ports [1] - All operations will strictly adhere to the terms and conditions of COSCO Shipping's bills of lading [1]

中东地区局势更新的服务提示（二） 尊敬的客户： 鉴于中东地区冲突持续升级，霍尔木兹海峡海上交通受到相应限制，为最大程度保障您的货物运输安全 及整体航运运营的稳定性，根据中远海运集运最新的风险评估结果，现决定即日起暂停相关航线新订舱 业务，恢复时间另行通知为止。涉及业务范围如下： 1、暂停全球至阿联酋（富查伊拉、豪尔费坎除外）、卡塔尔、巴林、伊拉克、沙特阿拉伯王国（吉达 除外）、科威特的所有新订舱业务。 2、暂停阿联酋（富查伊拉、豪尔费坎除外）、卡塔尔、巴林、伊拉克、沙特阿拉伯王国（吉达除 外）、科威特至全球的所有新订舱业务。 我司将持续关注中东地区事态发展，相关业务最新进展将通过公司官方网站及客服渠道更新。感谢您的 理解与支持。 中远海运集运 2026年3月4日 针对目前已在船的货物，我司正全面评估后续处置方案，包括研究确定可能的替代卸货港等相关事宜， 相关操作均将严格按照中远海运集运提单条款与条件执行。 ...

Group 1 - China Construction Bank's Chongqing Dianjiang Branch was penalized for violating financial statistical management regulations, payment settlement management regulations, and treasury management regulations [1][3][4] - The branch received a warning and was fined 984,700 yuan (approximately 98.47 million yuan) by the People's Bank of China, Changshou Branch [1][2][3]

Group 1 - The core viewpoint of the article highlights the significant decline in the software sector, with the S&P 500 Software and Services Index dropping over 20% year-to-date [1] - Deutsche Bank's report indicates that bearish bets against the U.S. software industry have reached the highest level since the 2008 financial crisis, reflecting increasing investor pessimism [1] - The average short interest in U.S. software companies has surged to over 5%, marking the highest level since the 2008-09 financial crisis when it peaked above 9% [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国银河策略 A股市场投资机会展望：A股剧烈波动并非趋势性转向，而是外围压力叠加下的短期情绪集中释放，中 长期市场向好趋势未变，后续将逐步从"情绪驱动"回归"基本面驱动"，呈现"震荡消化、动能提升、结 构聚焦"的运行格局。一是政策面持续发力，两会期间政策红利将集中释放，为市场提供明确的主线方 向；二是国内经济复苏基础逐步夯实，企业盈利有望持续改善，为市场提供基本面支撑；三是当前A股 估值仍处于合理水平，长线资金逐步入场，市场中长期向好趋势明确。配置机会上，建议重点关注：主 线一，短期确定性，涨价与避险。若地缘冲突短期内难以平息，全球实物资产正经历价值重估过程。霍 尔木兹海峡的紧张局势直接驱动能源及替代性需求走强。油气、石油化工（直接受益于油价上涨）、煤 炭（替代逻辑）；有色金属（铜、铝、黄金，受益于通胀预期和避险需求）；航运港口（运价飙升及航 线重构）。主线二，供需格局改善与行业盈利修复逻辑，以及估值具备安全边际的红利资产，建议关注 基础化工（业绩边际改善预期加强，如化学制品、化学原料、农化制品等）、钢铁、建筑材料、金融 （尤其是 ...

Core Viewpoint - China Construction Bank's Chaozhou branch was fined 260,000 yuan for violating regulations related to financial statistics, payment settlement, and financial technology management [1][2][3] Group 1: Administrative Penalty Details - The penalty was issued by the People's Bank of China, Chaozhou branch [1][2] - The decision was made on February 28, 2026, and the public disclosure period is set for three years [2][3] - The specific violation was categorized under financial statistics, payment settlement, and financial technology management regulations [1][2][3]

Core Viewpoint - Kanglong Chemical's stock experienced a slight increase of 0.07% on March 4, with a trading volume of 5.93 billion yuan and a market capitalization of 49.607 billion yuan [1] Group 1: Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to development [2] - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7] - As of September 30, Kanglong Chemical had 86,500 shareholders, a decrease of 1.62% from the previous period [8] Group 2: Financial Performance - For the period from January to September 2025, Kanglong Chemical achieved a revenue of 10.086 billion yuan, representing a year-on-year growth of 14.38%, while the net profit attributable to shareholders decreased by 19.76% to 1.141 billion yuan [8] - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.007 billion yuan distributed over the past three years [9] Group 3: Market Position and Trends - Kanglong Chemical is positioned within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, benefiting from trends in innovative drugs, CRO concepts, and artificial intelligence [2][8] - The company is focusing on digital transformation in clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through automation and machine learning [3]

Group 1 - The core point of the article is that the Agricultural Bank of China Limited, Hebei Branch, was fined 383,000 yuan for violating financial statistical management regulations [1][4][5] - The penalty was issued by the People's Bank of China, Hebei Branch, on February 26, 2026 [3][5] - The fine reflects regulatory enforcement in the financial sector, emphasizing the importance of compliance with statistical management standards [1][4]

Group 1 - Adidas reported an operating profit of €164 million for Q4 2025, with a net profit from continuing operations of €85 million, exceeding the forecast of €82.4 million [3] - For the full year of 2025, Adidas expects an operating profit of €2.06 billion and a net profit from continuing operations of €1.38 billion, slightly above the forecast of €1.36 billion [3] - The company anticipates an operating profit of approximately €2.3 billion for the full year of 2026, with a forecast of €2.69 billion [3]